Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co‐mixture with recombinant human hyaluronidase: A phase 1 randomized trial

AIM: Prior to the discontinuation of bococizumab's clinical development, it was considered advantageous to develop an infrequent dosing regimen (eg, monthly). Therefore, we conducted a phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of bococizumab when administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Bass, Almasa, Plotka, Anna, Mridha, Khurshid, Sattler, Catherine, Kim, Albert M., Plowchalk, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266420/
https://www.ncbi.nlm.nih.gov/pubmed/30623096
http://dx.doi.org/10.1002/hsr2.61

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266420/
https://www.ncbi.nlm.nih.gov/pubmed/30623096
http://dx.doi.org/10.1002/hsr2.61

Ejemplares similares